CD52 and graft versus host disease: These disturbances helped to minimize the risk of graft-versus-host disease (GVHD) and to acquire resistance to anti-CD52 alemtuzumab so that the CAR T cells are resistant to destruction and not eliminated from recipients when receiving alemtuzumab as a conditioning agent [32,34,66,68].